IFN-λ has demonstrated therapeutic utility against a variety of viral infections in human studies, including hepatitis C virus, hepatitis B virus, and SARS-CoV-2, as it is thought to confer protective antiviral activity without the damaging immune pathology induced by IFN-α/β treatment (5, 18). The gene discussed is IFNA1; the disease is viral infectious disease.